Q2 2024 Cardiff Oncology Inc Earnings Call Transcript
Key Points
- Cardiff Oncology Inc (CRDF) is actively enrolling patients in the CRDF-004 trial for RAS-mutated metastatic colorectal cancer, with 33 active sites and plans to enroll 90 patients.
- The company is leveraging Pfizer Ignite's resources to drive enrollment, which is progressing well and on track for an initial data readout later this year.
- Onvansertib has shown potential to shift the treatment paradigm for RAS-mutated mCRC, with no new therapies approved for this population in the past 20 years.
- The company is exploring onvansertib's efficacy in other cancer indications, including ovarian cancer resistant to PARP inhibitors, with promising preclinical data published in a peer-reviewed journal.
- Cardiff Oncology Inc (CRDF) has a strong financial position with $60.3 million in cash and short-term investments, providing a cash runway through the end of the third quarter of 2025.
- Enrollment in the CRDF-004 trial had previously been slower than anticipated, although it is now tracking well.
- The pancreatic cancer program is undergoing changes, with a shift to a new first-line trial combining onvansertib with NALIRIFOX, which may not be widely adopted as a standard of care.
- The company is still determining its path forward in ovarian cancer, indicating uncertainty in strategic direction for this indication.
- There are significant risks and uncertainties associated with forward-looking statements, which could materially affect actual results and timing of events.
- The company's cash runway guidance has been updated, indicating a potential need for additional funding beyond the third quarter of 2025.
Welcome to the Cardiff Oncology Second Quarter 2024 Financial Results and Business Update Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to turn the conference call over to Kiki Patel of Gilmartin Group. Please go ahead.
Thank you, operator. Joining us on the call today from Cardiff Oncology, our Chief Executive Officer, Mark Erlander, and Chief Financial Officer, Jamie Levine.
During this conference call, management will make forward-looking statements, including, without limitation, statements related to guidance, results and the timing of data readouts for onvansertib clinical trials. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties.
Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties.
Factors
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
